20 august biotech company Tyra Biosciences, which develops sensor inhibitors 1 fibroblast growth factor (FGFR) for the treatment of cancer in the preclinical stage of research work, filed an application with the Securities and Exchange Commission to raise up to 100 million dollars.
Tyra Biosciences is a clear oncology company, which specializes in the development of drugs for the treatment of tumor resistance. On the basis of its SNÅP site, the company develops next-generation contenders, specially designed to deal with the difficulty of gaining resistance to foods and finding other healing options. The company initially specialized in the development of a line of selective sensor inhibitors 1 fibroblast growth factor (FGFR). Its leading contender product, TYRA-300, is designed to selectively inhibit FGFR3 with a primary focus on bladder cancer patients.. Amid 2022 Tyra plans to apply for research on a new product for the TYRA-300.
Company headquartered in Carlsbad, California, was founded in 2018 year and plans to list on the stock exchange Nasdaq under the ticker TYRA. Tyra Biosciences has filed a secret application 28 May 2021 of the year. BofA Securities became the main organizers of the share issue, Jefferies и Cowen. Terms of the upcoming IPO were not disclosed.
